Search results for "eNOS"

showing 10 items of 1576 documents

Uncoupling of eNOS in Cardiovascular Disease

2017

Abstract Under physiological conditions, nitric oxide (NO) produced by the endothelial NO synthase (eNOS) represents a key vasoprotective factor. Under conditions of cardiovascular diseases, such as hypertension, diabetes, and atherosclerosis, eNOS may become uncoupled. Uncoupled eNOS generates superoxide at the expense of NO and contributes significantly to endothelial dysfunction and atherogenesis. Major mechanisms of eNOS uncoupling include depletion of tetrahydrobiopterin, an essential cofactor for the eNOS enzyme, and deficiency of l -arginine, the eNOS substrate, and/or eNOS S-glutathionylation. Reversal of eNOS uncoupling may represent a novel therapeutic strategy for the prevention …

0301 basic medicinemedicine.medical_specialtyArgininebiologySuperoxidebusiness.industryNitric Oxide Synthase Type IIITetrahydrobiopterin030204 cardiovascular system & hematologybiology.organism_classificationmedicine.diseaseVasoprotectiveNitric oxide03 medical and health scienceschemistry.chemical_compound030104 developmental biology0302 clinical medicineEndocrinologychemistryEnosInternal medicinemedicineEndothelial dysfunctionbusinessmedicine.drug
researchProduct

Treatment of multiple myeloma-related bone disease

2021

In this Policy Review, the Bone Working Group of the International Myeloma Working Group updates its clinical practice recommendations for the management of multiple myeloma-related bone disease. After assessing the available literature and grading recommendations using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) method, experts from the working group recommend zoledronic acid as the preferred bone-targeted agent for patients with newly diagnosed multiple myeloma, with or without multiple myeloma-related bone disease. Once patients achieve a very good partial response or better, after receiving monthly zoledronic acid for at least 12 months, the treating…

0301 basic medicinemedicine.medical_specialtyBone Density Conservation AgentBone disease03 medical and health sciences0302 clinical medicineSpinal cord compressionmedicineHumansMultiple myelomaBone Density Conservation Agentsbusiness.industrymedicine.diseaseSurgeryDiscontinuationTransplantationBone Density Conservation Agents030104 developmental biologyZoledronic acidDenosumabOncology030220 oncology & carcinogenesisPractice Guidelines as TopicBone DiseasesbusinessBone DiseaseMultiple Myelomamedicine.drugHumanThe Lancet Oncology
researchProduct

Effects of resveratrol on eNOS in the endothelium and the perivascular adipose tissue

2017

Under physiological conditions, nitric oxide (NO) is produced in the vasculature mainly by the endothelial NO synthase (eNOS). Experiments using gene-disrupted mice have demonstrated that eNOS has antihypertensive, antithrombotic, and antiatherosclerotic effects. Recent studies show that eNOS is expressed not only in the endothelium but also in the perivascular adipose tissue (PVAT). Resveratrol prevents eNOS uncoupling and upregulates eNOS expression and activity. These effects of resveratrol are well established for the eNOS enzyme in the endothelium. Interestingly, resveratrol also improves PVAT function. However, a causal role for eNOS in the effects of resveratrol on PVAT function has …

0301 basic medicinemedicine.medical_specialtyEndotheliumAdipose tissue030204 cardiovascular system & hematologyResveratrolGeneral Biochemistry Genetics and Molecular BiologyNitric oxide03 medical and health scienceschemistry.chemical_compound0302 clinical medicineHistory and Philosophy of ScienceEnosInternal medicineAntithromboticmedicinebiologyChemistryGeneral NeuroscienceNitric Oxide Synthase Type IIIbiology.organism_classificationNitric oxide synthase030104 developmental biologyEndocrinologymedicine.anatomical_structurebiology.proteinAnnals of the New York Academy of Sciences
researchProduct

Crucial role for Nox2 and sleep deprivation in aircraft noise-induced vascular and cerebral oxidative stress, inflammation, and gene regulation

2018

Abstract Aims Aircraft noise causes endothelial dysfunction, oxidative stress, and inflammation. Transportation noise increases the incidence of coronary artery disease, hypertension, and stroke. The underlying mechanisms are not well understood. Herein, we investigated effects of phagocyte-type NADPH oxidase (Nox2) knockout and different noise protocols (around-the-clock, sleep/awake phase noise) on vascular and cerebral complications in mice. Methods and results C57BL/6j and Nox2 −/− (gp91phox −/−) mice were exposed to aircraft noise (maximum sound level of 85 dB(A), average sound pressure level of 72 dB(A)) around-the-clock or during sleep/awake phases for 1, 2, and 4 days. Adverse effec…

0301 basic medicinemedicine.medical_specialtyEndotheliumAircraft10208 Institute of NeuropathologyInflammation610 Medicine & health030204 cardiovascular system & hematologySystemic inflammationmedicine.disease_cause2705 Cardiology and Cardiovascular Medicine03 medical and health sciences0302 clinical medicineBasic ScienceVascular BiologyInternal medicineeNOS uncouplingmedicineHumansEndothelial dysfunctionEndothelial dysfunctionInflammationSystemic inflammationbusiness.industryEnvironmental stressorCerebral redox balancemedicine.diseaseEnvironmental stressorSleep deprivationNoiseSleep deprivationOxidative Stress030104 developmental biologymedicine.anatomical_structureEndocrinologyNADPH oxidase-derived oxidative stress570 Life sciences; biologymedicine.symptombusinessNoiseCardiology and Cardiovascular MedicineOxidative stressNoise exposure
researchProduct

Chronic aspartame intake causes changes in the trans-sulphuration pathway, glutathione depletion and liver damage in mice

2017

No-caloric sweeteners, such as aspartame, are widely used in various food and beverages to prevent the increasing rates of obesity and diabetes mellitus, acting as tools in helping control caloric intake. Aspartame is metabolized to phenylalanine, aspartic acid, and methanol. Our aim was to study the effect of chronic administration of aspartame on glutathione redox status and on the trans-sulphuration pathway in mouse liver. Mice were divided into three groups: control; treated daily with aspartame for 90 days; and treated with aspartame plus N-acetylcysteine (NAC). Chronic administration of aspartame increased plasma alanine aminotransferase (ALT) and aspartate aminotransferase activities…

0301 basic medicinemedicine.medical_specialtyGlutamate-Cysteine LigaseClinical BiochemistryPhenylalanineBiochemistryMice03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineAspartic acidmedicineAnimalsHumansCysteineAspartamelcsh:QH301-705.5lcsh:R5-920S-adenosylmethionineMethioninebiologyAspartameChemistryOrganic ChemistryCystathionine gamma-LyaseMethionine AdenosyltransferaseGlutathioneGlutathioneCystathionine beta synthaseN-acetylcysteineAcetylcysteine030104 developmental biologyEndocrinologyGCLCGene Expression RegulationLiverlcsh:Biology (General)BiochemistrySweetening Agents030220 oncology & carcinogenesisbiology.proteinChemical and Drug Induced Liver Injurylcsh:Medicine (General)Research PaperCysteineRedox Biology
researchProduct

Treatments for post-menopausal osteoporotic women, what's new? How can we manage long-term treatment?

2016

Since the mid-1980s, postmenopausal osteoporosis (PMO) has been considered a serious public health concern because of the associated fractures. Pharmacological therapies that effectively reduce the number of fractures by improving bone mass have been and are being developed continuously. Most current agents inhibit bone loss by reducing bone resorption, but emerging therapies may increase bone mass by stimulating bone formation. Furthermore, nowadays, the most representative pharmaceuticals have been prescribed long enough to include the reporting of some adverse effects. This review discusses osteoporotic drugs that are approved or are under investigation for the treatment of post-menopaus…

0301 basic medicinemedicine.medical_specialtyLong term treatmentTime Factorsmedicine.medical_treatmentRomosozumab030209 endocrinology & metabolismPostmenopausal osteoporosisBone resorption03 medical and health sciences0302 clinical medicinemedicineHumansIntensive care medicineAdverse effectOsteoporosis PostmenopausalPharmacologybusiness.industryPublic healthBisphosphonateSurgery030104 developmental biologyDenosumabFemalebusinessmedicine.drugEuropean journal of pharmacology
researchProduct

Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy

2021

Summary The use of buffered soluble alendronate 70 mg effervescent tablet, a convenient dosing regimen for bisphosphonate therapy, seems a cost-effective strategy compared with relevant alternative treatments for postmenopausal women with osteoporosis aged 60 years and over in Italy. Introduction To assess the cost-effectiveness of buffered soluble alendronate (ALN) 70 mg effervescent tablet compared with relevant alternative treatments for postmenopausal osteoporotic women in Italy. Methods A previously validated Markov microsimulation model was adjusted to the Italian healthcare setting to estimate the lifetime costs (expressed in €2019) per quality-adjusted life-years (QALY) of buffered …

0301 basic medicinemedicine.medical_specialtyeconomic evaluationCost effectivenessCost-Benefit AnalysisEndocrinology Diabetes and Metabolismmedicine.medical_treatmentOsteoporosisUrology030209 endocrinology & metabolismAlendronate . Buffered soluble alendronate . Cost-effectiveness . Economic evaluation . Effervescent tablets . Osteoporosis . TreatmentAlendronate; Buffered soluble alendronate; Cost-effectiveness; Economic evaluation; Effervescent tablets; Osteoporosis; Treatment; Aged; Alendronate; Cost-Benefit Analysis; Female; Humans; Italy; Middle Aged; Observational Studies as Topic; Postmenopause; Quality-Adjusted Life Years; Tablets; Bone Density Conservation Agents; Osteoporosis; Osteoporosis Postmenopausal03 medical and health sciences0302 clinical medicinemedicineHumansEffervescent tabletOsteoporosis PostmenopausalAgedBone mineralPostmenopausal womenBone Density Conservation AgentstreatmentAlendronatebusiness.industrybuffered soluble alendronateMiddle AgedBisphosphonatemedicine.diseaseosteoporosisPostmenopauseObservational Studies as TopicDenosumabZoledronic acidItalyeffervescent tabletsPostmenopausalFemaleOriginal ArticleCost-effectivenessQuality-Adjusted Life Years030101 anatomy & morphologybusinessTabletsmedicine.drugOsteoporosis International
researchProduct

Corrigendum: Seabuckthorn Pulp Oil Protects against Myocardial Ischemia–Reperfusion Injury in Rats through Activation of Akt/eNOS

2016

Seabuckthorn (SBT) pulp oil obtained from the fruits of seabuckthorn [Hippophae rhamnoides L. (Elaeagnaceae)] has been used traditionally for its medicinal and nutritional properties. However, its role in ischemia–reperfusion (IR) injury of myocardium in rats has not been elucidated so far. The present study reports the cardioprotective effect of SBT pulp oil in IR-induced model of myocardial infarction in rats and underlying mechanism mediating activation of Akt/eNOS signaling pathway. Male albino Wistar rats were orally administered SBT pulp oil (5, 10, and 20 ml/kg/day) or saline for 30 days. On the day 31, ischemia was induced by one-stage ligation of left anterior descending coronary a…

0301 basic medicinenatural productsIschemia030204 cardiovascular system & hematologyPharmacologyseabuckthornmedicine.disease_causeLipid peroxidation03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEnosLactate dehydrogenaseMedicineoxidative stressPharmacology (medical)Original ResearchPharmacologylehberrybiologybusiness.industrylcsh:RM1-950apoptosisCorrectionbiology.organism_classificationmedicine.diseaseMalondialdehydemyocardial ischemia–reperfusion injury030104 developmental biologylcsh:Therapeutics. PharmacologyBiochemistrychemistryinflammationedible oilPulp (tooth)businessReperfusion injuryOxidative stressFrontiers in Pharmacology
researchProduct

Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disorders

2015

The pathogen safety of blood/plasma-derived products has historically been a subject of significant concern to the medical community, Measures such as donor selection and blood screening have contributed to increase the safety of these products, but pathogen transmission does still occur. Reasons for this include lack of sensitivity/specificity of current screening methods, lack of reliable screening tests for some pathogens (e.g. prions) and the fact that many potentially harmful infectious agents are not routinely screened for. Methods for the purification/inactivation of blood/plasma-derived products have been developed in order to further reduce the residual risk, but low concentrations…

0301 basic medicineriesgohumanosUltrafiltrationBacteremiaBlood DonorsHepacivirus030204 cardiovascular system & hematologyParasitemia/dk/atira/pure/subjectarea/asjc/2700/27200302 clinical medicineBlood plasmaScreening methodMedicinePathogenChromatographyultrafiltraciónfungemiaTransmission (medicine)Blood ScreeningbacteriemiaHematologyBlood Coagulation DisordersChromatography Ion ExchangeSettore MED/07 - Microbiologia e Microbiologia Clinicatransfusión de componentes sanguíneos/dk/atira/pure/subjectarea/asjc/2700/2730trastornos de la coagulación sanguíneaOncologyVIH-1RiskHepatitis B virusHaemophiliaBlood Component TransfusionHaemophiliaArticlepatógenos transmitidos por la sangre03 medical and health sciencesBlood-Borne PathogensHumansViremiacromatografíaBlood safety; Clotting; Haemophilia; Pathogen; TransfusionPathogenbusiness.industryDonor selectionTransfusionClottingdonantes de sangrevirus de la hepatitis Bmedicine.diseaseResidual risk030104 developmental biologyImmunologyHIV-1businessBlood safetyBlood Reviews
researchProduct

Response to: Comment on “Controversies about Interspinous Process Devices in the Treatment of Degenerative Lumbar Spine Diseases: Past, Present, and …

2017

030222 orthopedicsmedicine.medical_specialtyLumbar VertebraeGeneral Immunology and Microbiologybusiness.industrylcsh:Rlcsh:MedicineGeneral MedicineGeneral Biochemistry Genetics and Molecular BiologySurgery03 medical and health sciences0302 clinical medicineSpinal StenosisSpondylarthritismedicinePhysical therapyHumansLumbar spinebusinessProcess (anatomy)Letter to the Editor030217 neurology & neurosurgeryBioMed Research International
researchProduct